6612
奈米醫材
+1.30 (+1.87%)71.0031成交張數35.38本益比1.73股價淨值比1.88%殖利率2026-09-16資料日期
綜合損益表公開資訊觀測站申報原值 · 年度(第 4 季累計) · 每一格 = 該期對去年同期的成長率
營業收入20251,131年增 +31.5%
毛利率202559.1%最新一期
營業利益率202511.4%最新一期
每股盈餘20251.09年增 -54.8%
| 會計項目 | 走勢 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 營業收入合計 | – | +27.4% | -13.5% | +8.6% | +29.9% | +18.3% | +42.0% | +31.5% | |
| 營業成本合計 | – | -7.5% | -19.1% | +0.3% | +32.9% | +30.3% | +111.3% | +78.0% | |
| 營業毛利（毛損） | – | +41.4% | -12.0% | +10.6% | +29.3% | +15.6% | +24.3% | +11.4% | |
| 營業毛利（毛損）淨額 | – | +41.4% | -12.0% | +10.6% | +29.3% | +15.6% | +24.3% | +11.4% | |
| 推銷費用 | – | +14.5% | -19.1% | -0.8% | +58.8% | +7.7% | +86.7% | -14.9% | |
| 管理費用 | – | +17.8% | -2.4% | +10.8% | +18.7% | +20.6% | +42.7% | +48.8% | |
| 研究發展費用 | – | +121.1% | +7.8% | +6.7% | +26.9% | +33.3% | +8.6% | -17.5% | |
| 預期信用減損損失（利益） | – | +378.9% | -109.6% | – | -23.2% | +315.3% | -42.4% | -102.7% | |
| 營業費用合計 | – | +52.4% | -5.7% | +10.2% | +24.5% | +27.7% | +27.5% | +13.2% | |
| 營業利益（損失） | – | +22.5% | -25.6% | +11.9% | +42.0% | -12.9% | +13.5% | +4.3% | |
| 利息收入 | – | – | – | -56.4% | +200.5% | +95.3% | – | -44.2% | |
| 其他收入 | – | -24.2% | -49.8% | +80.0% | +8.0% | +14.1% | +131.7% | -6.3% | |
| 其他利益及損失淨額 | – | -137.4% | – | – | – | -78.0% | +120.1% | – | |
| 財務成本淨額 | – | +479.6% | -16.2% | -15.1% | -30.5% | – | +155.6% | +32.0% | |
| 採用權益法認列之關聯企業及合資損益之份額淨額 | – | – | – | – | – | – | – | +53.6% | |
| 營業外收入及支出合計 | – | -75.8% | -237.5% | – | – | -74.3% | +770.7% | -247.9% | |
| 稅前淨利（淨損） | – | +8.5% | -32.3% | -0.8% | +95.5% | -20.8% | +45.1% | -58.8% | |
| 所得稅費用（利益）合計 | – | +39.8% | -9.1% | -2.8% | -8.7% | +49.3% | +124.9% | -41.2% | |
| 繼續營業單位本期淨利（淨損） | – | -4.2% | -46.1% | +1.2% | +195.4% | -41.6% | -15.4% | -94.4% | |
| 本期淨利（淨損） | – | -4.2% | -46.1% | +1.2% | +195.4% | -41.6% | -15.4% | -94.4% | |
| 透過其他綜合損益按公允價值衡量之權益工具投資未實現評價損益 | – | – | – | +170.8% | -226.6% | – | -163.7% | – | |
| 與不重分類之項目相關之所得稅 | – | – | – | +170.7% | -226.6% | – | -163.7% | – | |
| 不重分類至損益之項目： | – | – | – | +170.8% | -226.6% | – | -163.7% | – | |
| 國外營運機構財務報表換算之兌換差額 | – | – | – | – | – | -128.0% | – | -178.9% | |
| 後續可能重分類至損益之項目： | – | – | – | – | – | -128.0% | – | -178.9% | |
| 其他綜合損益（淨額） | – | – | – | – | -19.7% | -149.7% | – | -183.7% | |
| 本期綜合損益總額 | – | -34.8% | -26.7% | +67.4% | +132.9% | -52.5% | +93.2% | -140.5% | |
| 母公司業主（淨利∕損） | – | +15.0% | -35.9% | +12.9% | +120.0% | -24.2% | +5.5% | -50.3% | |
| 非控制權益（淨利∕損） | – | – | – | – | – | – | – | – | |
| 母公司業主（綜合損益） | – | -13.0% | -20.5% | +62.2% | +89.2% | -31.7% | +65.0% | -103.7% | |
| 非控制權益（綜合損益） | – | – | – | – | – | – | – | – | |
| 基本每股盈餘 | – | +9.0% | -36.2% | +12.3% | +119.0% | -26.2% | -14.2% | -54.8% | |
| 稀釋每股盈餘 | – | +9.5% | -36.4% | +13.0% | +117.8% | -26.4% | -14.0% | -55.0% |
金額為公司申報原值除以一千(百萬元,四捨五入),每股金額為元。年度為第 4 季的年初至今累計數。走勢條是歷史各期的相對大小,藍為正、綠為負。年增以去年同期為基期,基期非正數或變動超過十倍時不列。 權益變動表在申報資料分頁。